Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.

Jun MoriYasuhisa OhataYasuko FujisawaYukihito SatoSebastian RöhrichMichael Højby RasmussenRikke Beck BangReiko Horikawa

Published in: Clinical endocrinology (2024)

Somapacitan showed sustained efficacy in Japanese children with GHD over 104 weeks and for 52 weeks after switching from daily GH. Somapacitan was well tolerated and preferred over daily GH.

Keyphrases

growth hormone
clinical trial
young adults
physical activity
gestational age
open label
replacement therapy